Prostate Cancer - Results from #120

Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer. April 19, 2022

Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review. April 19, 2022

Radium-223 in the Treatment of Metastatic Castrate-Resistant Prostate Cancer. April 19, 2022

Gut environment changes due to androgen deprivation therapy in patients with prostate cancer. April 19, 2022

Does Androgen Deprivation for Prostate Cancer Affect Normal Adaptation to Resistance Exercise? April 19, 2022

LHRH Sparing Therapy in Patients with Chemotherapy-Naïve, mCRPC Treated with Abiraterone Acetate plus Prednisone: Results of the Randomized Phase II SPARE Trial April 18, 2022

Dietary inflammatory index and prostate cancer risk: MCC-Spain study. April 18, 2022

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. April 18, 2022

A deep learning masked segmentation alternative to manual segmentation in biparametric MRI prostate cancer radiomics. April 18, 2022

Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression? April 18, 2022

Adjuvant or Salvage Radiation Therapy for Prostate Cancer after Prostatectomy: Current Status, Controversies and Perspectives. April 18, 2022

RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminoma. April 18, 2022

Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. April 15, 2022

Acute Toxicity of Ultrahypofractionation Compared to Moderate Hypofractionation in Prostate Cancer Treatment - a Randomized Trial. April 15, 2022

Randomized Trial of Conventional- vs Conventional plus Fluciclovine (18F) PET/CT-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer: Volumetric and Patient-Reported Toxicity Analyses. April 15, 2022

Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer. April 15, 2022

A Phase 1b/2 Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men With Metastatic Castration-Resistant Prostate Cancer with Progression on an Androgen Receptor Targeting Agent. April 15, 2022

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). April 14, 2022

The quality of life of regional and remote cancer caregivers in Australia. April 14, 2022

Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management. April 14, 2022

Page 7 of 1223

email news signup